-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Downgrades Passage Bio to Neutral, Lowers Price Target to $8

Benzinga·04/21/2026 13:24:25
Listen to the news
Wedbush analyst Yun Zhong downgrades Passage Bio (NASDAQ:PASG) from Outperform to Neutral and lowers the price target from $32 to $8.